Ozempic

GLP-1 drugs: clinical trends, safety, and market shifts

315 clusters · 1160 sources · last updated about 4 hours ago

Latest: GLP-1 weight loss drugs drive surge in protein-based products

The clinical and economic landscape of GLP-1 medications continues to expand. Beyond obesity, research indicates potential benefits for psychiatric, respiratory, and neurodegenerative health. A large-scale U.S. study sug

Heineken response to GLP-1 medication impact

2 clusters · 20 sources · last updated 2 days ago

Latest: Heineken warns UK pubs of shifting habits due to GLP-1 drugs

Heineken has advised British hospitality venues to prepare for potential revenue declines caused by the rising popularity of GLP-1 weight-loss medications, such as Ozempic and Wegovy. The company identified two primary

GLP-1 weight-loss drug market trends

2 clusters · 5 sources · last updated 2 days ago

Latest: Pharmaceutical trends shift from weight loss to hair regrowth

The rise of GLP-1 weight-loss drugs, such as Ozempic, has created secondary market opportunities and medical concerns. In the cosmetics sector, the British chemical company Croda has seen a resurgence due to the demand f

Novo Nordisk pivots strategy to counter patent cliff

112 clusters · 548 sources · last updated 2 days ago

Latest: Novo Nordisk faces intense competition in obesity drug market

Novo Nordisk is implementing a strategic reset to address long-term growth concerns and the looming patent expiration of semaglutide in the early 2030s. To diversify its portfolio and counter competition from Eli Lilly,

Ozempic medical uses and reported effects

3 clusters · 6 sources · last updated 4 days ago

Latest: Monserrat Álvarez reports adverse side effects from Ozempic use

Ozempic, a medication approved by the FDA and EMA for treating type 2 diabetes, is increasingly utilized for weight management through off-label prescriptions. Users have reported significant weight reduction and improve

Expanding therapeutic uses and regulatory approvals for GLP-

33 clusters · 154 sources · last updated 4 days ago

Latest: GLP-1 medications show weight loss challenges regarding muscle mass and maintenance

Medical research continues to expand the therapeutic potential of GLP-1 receptor agonists like semaglutide and tirzepatide. While semaglutide is widely used for weight loss and diabetes, new evidence suggests it may slow

Medication consumption and adverse reactions in Portugal

2 clusters · 11 sources · last updated 12 days ago

Latest: Infarmed reports daily adverse reactions for weight loss drugs in Portugal

Data from the 2025 National Health Survey (INS 2025) indicated that 33.2% of the Portuguese population aged 15 and older consumed non-prescription medications. This usage was most prevalent in the 35 to 44 age group (40.

Social media trends promoting extreme thinness

2 clusters · 6 sources · last updated 15 days ago

Latest: Social media trends see resurgence of ‘Skinny Chic’ beauty standards

Social media platforms are experiencing a resurgence of beauty standards centered on extreme thinness, often referred to as ‘Skinny Chic’. This shift marks a departure from the body positivity movement that gained promin

WHO childhood obesity management guidelines

3 clusters · 67 sources · last updated 16 days ago

Latest: WHO issues first global guidelines for childhood obesity management

The World Health Organization (WHO) has released its first global guidelines for the integrated management of obesity in children and adolescents aged 0 to 19. This follows reports that obesity prevalence in this age gro

Novo Nordisk corporate rebranding and health initiatives

3 clusters · 42 sources · last updated 28 days ago

Latest: Novo rebrands to simplify identity and signal future medical innovations

Novo Nordisk has initiated several strategic moves regarding its brand identity and public health engagement. The company entered a partnership with the Norwegian football club Bodø/Glimt to promote physical activity and